Beam Therapeutics Newsroom

H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80

Futu NewsNov 7 01:32

Beam Therapeutics Is Maintained at Sector Perform by RBC Capital

Dow JonesNov 7 00:10

Scotiabank Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Cuts Target Price to $24

Futu NewsNov 6 21:31

A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $31 to $69

Futu NewsNov 6 21:08

Beam Therapeutics Analyst Ratings

BenzingaNov 6 20:29

JonesTrading Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

TipRanksNov 6 05:27

Buy Rating Affirmed for Beam Therapeutics Due to Promising BEAM-101 Developments in Sickle Cell Disease Treatment

TipRanksNov 5 23:40

William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating

Futu NewsOct 31 18:31

Beam Therapeutics Analyst Ratings

BenzingaOct 16 22:32

Scotiabank Initiates Beam Therapeutics at Sector Perform With $24 Price Target

MT NewswiresOct 16 20:23

Beam Therapeutics Price Target Maintained With a $27.00/Share by RBC Capital

Dow JonesSep 19 21:31

RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $27

Futu NewsSep 19 19:31

RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)

TipRanksSep 19 18:47

JonesTrading Initiates Beam Therapeutics(BEAM.US) With Hold Rating

Futu NewsSep 18 04:31

Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $69

Futu NewsSep 12 10:32

Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $69

Futu NewsSep 12 00:31

Beam Therapeutics Is Maintained at Buy by Stifel

Dow JonesSep 11 19:52

Beam Therapeutics Analyst Ratings

BenzingaAug 22 20:50

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

BenzingaAug 22 20:50

H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80

Futu NewsAug 22 20:33